Intellectia LogoIntellectia
Product
Resources
Markets
News
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
Crypto Technical Analysis
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Earnings Trading
Stock Chart Patterns
Daytrading Center

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks
NewsPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. KNSA
stocks logo

KNSA

-
Add to WatchlistAdvanced Chart
$
0.000
0(0.000%)1D
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q3
FY2025Q4
FY2026Q1
164.79M
+46.85%
0.391
-317.37%
178.06M
+45.31%
0.444
-470.22%
189.30M
+37.39%
0.240
+118.18%
Estimates Revision
The market is revising Upward the revenue expectations for Kiniksa Pharmaceuticals International, plc (KNSA) for FY2025, with the revenue forecasts being adjusted by 1.11% over the past three months. During the same period, the stock price has changed by 22.75%.
Revenue Estimates for FY2025
Revise Upward
up Image
+1.11%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
up Image
+5.86%
In Past 3 Month
Stock Price
Go Up
up Image
+22.75%
In Past 3 Month
5 Analyst Rating
up Image0
Wall Street analysts forecast KNSA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for KNSA is 40.80 USD with a low forecast of 35.00 USD and a high forecast of 47.00  USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Buy
0 Hold
0 Sell
Strong Buy
up Image0
Current: 33.070
sliders
Low
35.00
Averages
40.80
High
47.00
up Image0
Current: 33.070
sliders
Low
35.00
Averages
40.80
High
47.00
Jefferies
Buy
maintain
$45 -> $54
2025-07-29
Reason
Jefferies
Price Target
$45 -> $54
2025-07-29
maintain
Buy
Reason
Jefferies raised the firm's price target on Kiniksa to $54 from $45 and keeps a Buy rating on the shares after what the firm points out was "another 'beat & raise'" report following a "greatly positive" Q1. The firm sees strong commercial execution, continued growth on all launch metrics, and meaningful upside from further deepening the penetration into the target population as well as potential expansion into a larger population of patients, the analyst tells investors.
Wells Fargo
NULL -> Overweight
upgrade
$30 -> $42
2025-07-09
Reason
Wells Fargo
Price Target
$30 -> $42
2025-07-09
upgrade
NULL -> Overweight
Reason
Wells Fargo raised the firm's price target on Kiniksa to $42 from $30 and keeps an Overweight rating on the shares. The firm's Q2 Arcalyst estimates of $146M are in line with the Street, and it forecasts continued growth through 2025. As KPL-387's trial initiates in mid-25, all eyes are on Arcalyst this year and its market share in early lines, adds Wells.
Wedbush
David Nierengarten
Buy
Reiterates
$34
2025-04-16
Reason
Wedbush
David Nierengarten
Price Target
$34
2025-04-16
Reiterates
Buy
Reason
Citigroup
Geoff Meacham
Strong Buy
Initiates
$40
2025-03-13
Reason
Citigroup
Geoff Meacham
Price Target
$40
2025-03-13
Initiates
Strong Buy
Reason
Citi initiated coverage of Kiniksa with a Buy rating and $40 price target. Healthcare policy remains a key biopharma sector uncertainty but major economic worries have underscored the defensive attributes of biotech, the analyst tells investors in a research note. The firm says that despite near-term "choppiness," a "barbell approach" to the sector still makes sense with higher-growth large caps likely able to absorb potential policy headwinds and catalyst-driven small-cap biotechs being insulated from macro uncertainties. Citi's preferred smaller caps are focused on unmet medical needs, have differentiated research and development platforms or are "clean growth stories." The firm highlights Apogee, Avidity, and Kymera as favorites.
JP Morgan
Anupam Rama
Buy
Maintains
$39 → $40
2024-11-05
Reason
JP Morgan
Anupam Rama
Price Target
$39 → $40
2024-11-05
Maintains
Buy
Reason
Evercore ISI Group
Liisa Bayko
Buy
Maintains
$30 → $35
2024-10-30
Reason
Evercore ISI Group
Liisa Bayko
Price Target
$30 → $35
2024-10-30
Maintains
Buy
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for Kiniksa Pharmaceuticals International PLC (KNSA.O) is 22.64, compared to its 5-year average forward P/E of -291.84. For a more detailed relative valuation and DCF analysis to assess Kiniksa Pharmaceuticals International PLC 's fair value, click here.
    Forward PE
    Forward EV/EBITDA
    Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-291.84
Current PE
22.64
Overvalued PE
975.31
Undervalued PE
-1559.00

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-28.36
Current EV/EBITDA
16.28
Overvalued EV/EBITDA
121.30
Undervalued EV/EBITDA
-178.01

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
21.44
Current PS
3.21
Overvalued PS
82.38
Undervalued PS
-39.50

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
N/A
ROIC

Trading Trends

    Insider
    Hedge Fund
    Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought

KNSA News & Events

Events Timeline

(ET)
2025-07-29
07:36:42
Kiniksa raises FY25 ARCALYST revenue view to $625M-$640M from $590M-$605M
select
2025-07-29
07:35:40
Kiniksa reports Q2 EPS 23c, consensus 26c
select
2025-06-05 (ET)
2025-06-05
07:03:40
Kiniksa announces details for planned 2/3 trial of KPL-387
select
Sign Up For More Events
Sign Up For More Events

News

Preview
8.5
08-04Benzinga
Why CommScope Shares Are Trading Higher By Around 40%; Here Are 20 Stocks Moving Premarket

  • CommScope Stock Surge: Shares of CommScope Holding Company rose 40.1% in pre-market trading after reports that Amphenol is close to acquiring its Broadband arm.

  • Market Movements: Several other stocks experienced significant changes, with Psyence Biomedical gaining 116.4%, while Replimune Group saw a decline of 38% in pre-market trading.

Preview
4.0
07-30Benzinga
Jefferies Maintains Buy on Kiniksa Pharmaceuticals, Raises Price Target to $54

  • Real-time Intelligence for Traders: Benzinga Pro offers the fastest news alerts and real-time intelligence to help traders succeed in the stock market.

  • Exclusive Community Access: Joining Benzinga Pro connects you with over 10,000 serious traders and provides access to exclusive stories and insights from Benzinga reporters.

Preview
9.5
07-29Newsfilter
Kiniksa Pharmaceuticals Reports Second Quarter 2025 Financial Results and Recent Portfolio Execution

  • Financial Performance: Kiniksa Pharmaceuticals reported a net product revenue of $156.8 million for Q2 2025, marking a 52% year-over-year growth, and has raised its ARCALYST sales guidance to between $625 million and $640 million for the year.

  • Clinical Developments: The company has initiated a Phase 2/3 clinical trial for KPL-387 in recurrent pericarditis, with data expected in late 2026, while maintaining a strong cash balance of $307.8 million as of June 30, 2025.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Kiniksa Pharmaceuticals International PLC (KNSA) stock price today?

The current price of KNSA is 33.07 USD — it has increased 0.36 % in the last trading day.

arrow icon

What is Kiniksa Pharmaceuticals International PLC (KNSA)'s business?

Kiniksa Pharmaceuticals International, plc is a biopharmaceutical company focused on discovering, acquiring, developing and commercializing novel therapies for diseases with unmet need, with a focus on cardiovascular indications. Its portfolio of assets is based on strong biologic rationale or validated mechanisms and offers the potential for differentiation. Its ARCALYST is used for the treatment of recurrent pericarditis and reduces the risk of recurrence in adults and children 12 years and older. ARCALYST is also approved for the treatment of Cryopyrin-Associated Periodic Syndromes (CAPS), including Familial Cold Autoinflammatory Syndrome (FCAS) and Muckle-Wells Syndrome, and the maintenance of remission in Deficiency of Interleukin-1 Receptor Antagonist. Its other portfolio includes KPL-387, KPL-1161, Abiprubart, and Mavrilimumab. Mavrilimumab is an investigational monoclonal antibody inhibitor targeting granulocyte-macrophage colony stimulating factor receptor alpha.

arrow icon

What is the price predicton of KNSA Stock?

Wall Street analysts forecast KNSA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for KNSA is 40.80 USD with a low forecast of 35.00 USD and a high forecast of 47.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Kiniksa Pharmaceuticals International PLC (KNSA)'s revenue for the last quarter?

Kiniksa Pharmaceuticals International PLC revenue for the last quarter amounts to 156.80M USD, increased 44.34 % YoY.

arrow icon

What is Kiniksa Pharmaceuticals International PLC (KNSA)'s earnings per share (EPS) for the last quarter?

Kiniksa Pharmaceuticals International PLC. EPS for the last quarter amounts to 0.23 USD, decreased -483.33 % YoY.

arrow icon

What changes have occurred in the market's expectations for Kiniksa Pharmaceuticals International PLC (KNSA)'s fundamentals?

The market is revising Upward the revenue expectations for Kiniksa Pharmaceuticals International, plc (KNSA) for FY2025, with the revenue forecasts being adjusted by 1.11% over the past three months. During the same period, the stock price has changed by 22.75%.
arrow icon

How many employees does Kiniksa Pharmaceuticals International PLC (KNSA). have?

Kiniksa Pharmaceuticals International PLC (KNSA) has 315 emplpoyees as of August 06 2025.

arrow icon

What is Kiniksa Pharmaceuticals International PLC (KNSA) market cap?

Today KNSA has the market capitalization of 2.45B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerCrypto Technical AnalysisAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings Trading
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySitemap
Start for Free